Kala Pharmaceuticals KALA 深 沪
已收盘 08-08 16:00:00 美东时间
7.38
+0.220
+3.07%
华盛通- 最 高7.71
- 今 开7.12
- 成交量 10.85万股
- 最 低 7.0502
- 昨 收 7.16
- 总市值 4761.87万
- 52周最高 11.20
- 市盈率 静 --
- 换手率 1.68%
- 52周最低 2.92
- 委 比 -80.69%
- 总股本 645.24万
- 历史最高 1337.50
- 量 比 0.92
- 振 幅 9.22%
- 历史最低 2.92
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kala Bio Q2 EPS $(1.71) Beats $(1.82) Estimate
Kala Bio (NASDAQ:KALA) reported quarterly losses of $(1.71) per share which beat the analyst consensus estimate of $(1.82) by 6.04 percent. This is a 45.89 percent increase over losses of $(3.16) per share from the same
08-08 21:44
KALA BIO Non-GAAP EPS of -$1.71
KALA BIO press release (NASDAQ:KALA): Q2 Non-GAAP EPS of -$1.71. Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 More on KALA BIO Seeking Alpha’s Quant Ra...
08-08 20:07
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
KALA BIO, Inc. has completed patient enrollment in the Phase 2b CHASE trial for KPI-012 in Persistent Corneal Epithelial Defect (PCED) and expects topline data by the end of September 2025. The company reported $31.9 million in cash as of June 30, 2025, which is expected to fund operations into the first quarter of 2026. KALA is focused on advancing its MSC-S platform for rare ocular diseases and explored KPI-012's potential for additional indica...
08-08 12:00
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
KALA BIO, Inc. announced that its management will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. They will deliver a pre-recorded presentation and join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications." KALA is a clinical-stage biopharmaceutical company focused on developing therapies for rare eye diseases. Its lead product, KPI-012, targets persistent corneal epithelial ...
08-06 12:00
Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial
Kala Pharmaceuticals ( ($KALA) ) has provided an update. On July 9, 2025, KALA ...
07-09 20:28
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
KALA BIO, Inc. will host a webcast on July 16, 2025, at 4:00 p.m. ET, featuring Key Opinion Leaders discussing KPI-012 for treating persistent corneal epithelial defect (PCED). Speakers will cover PCED overview, patient journey, mesenchymal stem cell secretome (MSC-S), KPI-012, and clinical trial insights. Todd Bazemore will discuss commercial opportunities and milestones. Q&A and registration details are available; an archived replay will follow...
07-07 12:00
KALA BIO to Present at Jefferies Global Healthcare Conference
KALA BIO, Inc. announced that its management will present at the Jefferies Global Healthcare Conference on June 5, 2025, in New York. The presentation will discuss KALA's innovative therapies for rare eye diseases, particularly its lead product candidate, KPI-012, which is in clinical development for treating Persistent Corneal Epithelial Defect (PCED). KPI-012 has received Orphan Drug and Fast Track designations from the FDA and is also being ev...
05-29 12:00
美股大行评级 | 潜在涨幅112.77%！Craig-Hallum上调PLAYSTUDIOS目标价至3美元，评级升至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1132955525493317632.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Craig-Hallum：上调PLAYSTUDIOS(MYPS)评级至"买入"，目标价从2美元升至3美元</p> <p>• Leerink Partners：上调Fulcrum Therapeutics(FULC)评级至"
05-24 08:40
HC Wainwright & Co. Maintains Buy on Kala Bio, Lowers Price Target to $12
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $15 to $12.
05-23 19:06
Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate
Kala Bio (NASDAQ:KALA) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.03) by 30.54 percent. This is a 66.43 percent increase over losses of $(4.20) per share from the same
05-14 20:11
